Cargando…
Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients
BACKGROUND: Lauren-classification and human epidermal growth factor receptor 2 (HER2) status are two important pathological features of gastric cancer patients. The prognostic value of HER2 in gastric cancer remains controversial. Intestinal type gastric cancer has better prognosis and higher HER2 p...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289219/ https://www.ncbi.nlm.nih.gov/pubmed/25380654 http://dx.doi.org/10.1186/1471-2407-14-823 |
_version_ | 1782352068601708544 |
---|---|
author | Qiu, Miaozhen Zhou, Yixin Zhang, Xinke Wang, Zixian Wang, Fang Shao, Jianyong Lu, Jiabin Jin, Ying Wei, Xiaoli Zhang, Dongsheng Wang, Fenghua Li, Yuhong Yang, Dajun Xu, Ruihua |
author_facet | Qiu, Miaozhen Zhou, Yixin Zhang, Xinke Wang, Zixian Wang, Fang Shao, Jianyong Lu, Jiabin Jin, Ying Wei, Xiaoli Zhang, Dongsheng Wang, Fenghua Li, Yuhong Yang, Dajun Xu, Ruihua |
author_sort | Qiu, Miaozhen |
collection | PubMed |
description | BACKGROUND: Lauren-classification and human epidermal growth factor receptor 2 (HER2) status are two important pathological features of gastric cancer patients. The prognostic value of HER2 in gastric cancer remains controversial. Intestinal type gastric cancer has better prognosis and higher HER2 positive proportion. What is the interaction between these two factors? We hypothesized that a combination of Lauren-classification and human epidermal growth factor receptor 2 (HER2) status (L-H status) might be more meaningful than either factor alone. METHODS: We collected 838 gastric cancer patients at all stages who had received treatment in our cancer center. This study was registered in the website of ClinicalTrials.Gov, with the number NCT01927146. We divided the patients into six groups according to their L-H status: Group A, HER2 negative and intestinal type; Group B, HER2 positive and intestinal type; Group C, HER2 negative and diffuse type; Group D, HER2 positive and diffuse type; Group E, HER2 negative and mixed type; and Group F, HER2 positive and mixed type. RESULTS: Diffuse type and intestinal type accounted for 51.0% and 33.9%, respectively. The proportion of HER2 positive patients was 11.2%, 25.4%, 2.1% and 10.2% in the whole patient group, intestinal, diffuse and mixed type, respectively. Median overall survival was 34.0 months, 25.3 months, 27.6 months, 19.2 months, 25.9 months and 26.4 months in the six groups patients, P = 0.053. There was a significant difference in survival among the first four groups (P < 0.001). HER2 was an independent prognostic factor in the intestinal type and in stage I + II patients, but not in the diffuse type or stage III + IV patients. L-H status was an independent prognostic factor in patients at all stages. For the diffuse and intestinal types, the multivariate analysis showed that HER2 was not an independent prognostic factor, while Lauren classification and L-H status were. Moreover, L-H status was a better prognostic factor than the Lauren classification. CONCLUSIONS: L-H status is a prognostic factor in diffuse and intestinal type patients, but not in the mixed type. Patients with HER2 negative and intestinal type had the best survival, while patients with HER2 positive status and diffuse type had the worst survival. |
format | Online Article Text |
id | pubmed-4289219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42892192015-01-11 Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients Qiu, Miaozhen Zhou, Yixin Zhang, Xinke Wang, Zixian Wang, Fang Shao, Jianyong Lu, Jiabin Jin, Ying Wei, Xiaoli Zhang, Dongsheng Wang, Fenghua Li, Yuhong Yang, Dajun Xu, Ruihua BMC Cancer Research Article BACKGROUND: Lauren-classification and human epidermal growth factor receptor 2 (HER2) status are two important pathological features of gastric cancer patients. The prognostic value of HER2 in gastric cancer remains controversial. Intestinal type gastric cancer has better prognosis and higher HER2 positive proportion. What is the interaction between these two factors? We hypothesized that a combination of Lauren-classification and human epidermal growth factor receptor 2 (HER2) status (L-H status) might be more meaningful than either factor alone. METHODS: We collected 838 gastric cancer patients at all stages who had received treatment in our cancer center. This study was registered in the website of ClinicalTrials.Gov, with the number NCT01927146. We divided the patients into six groups according to their L-H status: Group A, HER2 negative and intestinal type; Group B, HER2 positive and intestinal type; Group C, HER2 negative and diffuse type; Group D, HER2 positive and diffuse type; Group E, HER2 negative and mixed type; and Group F, HER2 positive and mixed type. RESULTS: Diffuse type and intestinal type accounted for 51.0% and 33.9%, respectively. The proportion of HER2 positive patients was 11.2%, 25.4%, 2.1% and 10.2% in the whole patient group, intestinal, diffuse and mixed type, respectively. Median overall survival was 34.0 months, 25.3 months, 27.6 months, 19.2 months, 25.9 months and 26.4 months in the six groups patients, P = 0.053. There was a significant difference in survival among the first four groups (P < 0.001). HER2 was an independent prognostic factor in the intestinal type and in stage I + II patients, but not in the diffuse type or stage III + IV patients. L-H status was an independent prognostic factor in patients at all stages. For the diffuse and intestinal types, the multivariate analysis showed that HER2 was not an independent prognostic factor, while Lauren classification and L-H status were. Moreover, L-H status was a better prognostic factor than the Lauren classification. CONCLUSIONS: L-H status is a prognostic factor in diffuse and intestinal type patients, but not in the mixed type. Patients with HER2 negative and intestinal type had the best survival, while patients with HER2 positive status and diffuse type had the worst survival. BioMed Central 2014-11-07 /pmc/articles/PMC4289219/ /pubmed/25380654 http://dx.doi.org/10.1186/1471-2407-14-823 Text en © Qiu et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Qiu, Miaozhen Zhou, Yixin Zhang, Xinke Wang, Zixian Wang, Fang Shao, Jianyong Lu, Jiabin Jin, Ying Wei, Xiaoli Zhang, Dongsheng Wang, Fenghua Li, Yuhong Yang, Dajun Xu, Ruihua Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients |
title | Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients |
title_full | Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients |
title_fullStr | Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients |
title_full_unstemmed | Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients |
title_short | Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients |
title_sort | lauren classification combined with her2 status is a better prognostic factor in chinese gastric cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289219/ https://www.ncbi.nlm.nih.gov/pubmed/25380654 http://dx.doi.org/10.1186/1471-2407-14-823 |
work_keys_str_mv | AT qiumiaozhen laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT zhouyixin laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT zhangxinke laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT wangzixian laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT wangfang laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT shaojianyong laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT lujiabin laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT jinying laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT weixiaoli laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT zhangdongsheng laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT wangfenghua laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT liyuhong laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT yangdajun laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients AT xuruihua laurenclassificationcombinedwithher2statusisabetterprognosticfactorinchinesegastriccancerpatients |